158 related articles for article (PubMed ID: 35839046)
1. PD-1, PD-L1, NY-ESO-1, and MAGE-A4 expression in cutaneous angiosarcoma: A case report.
Hashimoto K; Nishimura S; Shinyashiki Y; Ito T; Tanaka H; Ohtani K; Kakinoki R; Akagi M
Medicine (Baltimore); 2022 Jul; 101(28):e29621. PubMed ID: 35839046
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical expression and clinicopathological assessment of PD-1, PD-L1, NY-ESO-1, and MAGE-A4 expression in highly aggressive soft tissue sarcomas.
Hashimoto K; Nishimura S; Ito T; Kakinoki R; Akagi M
Eur J Histochem; 2022 Apr; 66(2):. PubMed ID: 35448937
[TBL] [Abstract][Full Text] [Related]
3. The programmed cell death protein-1/programmed cell death ligand 1 expression, CD3+ T cell infiltration, NY-ESO-1 expression, and microsatellite instability phenotype in primary cutaneous melanoma and mucosal melanoma and their clinical significance and prognostic value: a study of 89 consecutive cases.
Ren Y; Lv Q; Yue W; Liu B; Zou Z
Melanoma Res; 2020 Feb; 30(1):85-101. PubMed ID: 31095042
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma.
Chen K; Cheng G; Zhang F; Zhang N; Li D; Jin J; Wu J; Ying L; Mao W; Su D
Oncotarget; 2016 May; 7(21):30772-80. PubMed ID: 27120796
[TBL] [Abstract][Full Text] [Related]
5. Soluble PD-L1 Concentration Is Proportional to the Expression of PD-L1 in Tissue and Is Associated with a Poor Prognosis in Esophageal Squamous Cell Carcinoma.
Shiraishi T; Toyozumi T; Sakata H; Murakami K; Kano M; Matsumoto Y; Yokoyama M; Okada K; Kamata T; Ryuzaki T; Kinoshita K; Hirasawa S; Matsubara H
Oncology; 2022; 100(1):39-47. PubMed ID: 34991094
[TBL] [Abstract][Full Text] [Related]
6. Programmed cell death-ligand 1 expression predicts poor treatment response and prognostic value in esophageal squamous cell carcinoma patients without esophagectomy.
Zhang F; Zhu X; Zhang Q; Zhou P; Hao L
Aging (Albany NY); 2021 Jul; 13(14):18827-18838. PubMed ID: 34297698
[TBL] [Abstract][Full Text] [Related]
7. Regulation of programmed cell death ligand 1 expression by atypical protein kinase C lambda/iota in cutaneous angiosarcoma.
Kawamura A; Kawamura T; Riddell M; Hikita T; Yanagi T; Umemura H; Nakayama M
Cancer Sci; 2019 May; 110(5):1780-1789. PubMed ID: 30801864
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 expression and its clinicopathological correlation in advanced esophageal squamous cell carcinoma in a Chinese population.
Rong L; Liu Y; Hui Z; Zhao Z; Zhang Y; Wang B; Yuan Y; Li W; Guo L; Ying J; Song Y; Wang L; Zhou Z; Xue L; Lu N
Diagn Pathol; 2019 Jan; 14(1):6. PubMed ID: 30684971
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic modulation combined with PD-1/PD-L1 blockade enhances immunotherapy based on MAGE-A11 antigen-specific CD8+T cells against esophageal carcinoma.
Wu Y; Sang M; Liu F; Zhang J; Li W; Li Z; Gu L; Zheng Y; Li J; Shan B
Carcinogenesis; 2020 Jul; 41(7):894-903. PubMed ID: 32529260
[TBL] [Abstract][Full Text] [Related]
10. Melanoma-associated antigen-A and programmed death-ligand 1 expression are associated with advanced urothelial carcinoma.
Faiena I; Astrow SH; Elashoff DA; Jain R; Bot A; Chamie K; Belldegrun AS; Pantuck AJ; Drakaki A
Cancer Immunol Immunother; 2019 May; 68(5):743-751. PubMed ID: 30790015
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma.
Jiang Y; Lo AWI; Wong A; Chen W; Wang Y; Lin L; Xu J
Oncotarget; 2017 May; 8(18):30175-30189. PubMed ID: 28404915
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 expression on tumor cells associated with favorable prognosis in surgically resected esophageal squamous cell carcinoma.
Guo W; Zhang F; Shao F; Wang P; Li Z; Yang X; He Z; Shi S; Gao Y; He J
Hum Pathol; 2019 Feb; 84():291-298. PubMed ID: 30296523
[TBL] [Abstract][Full Text] [Related]
13. Tumor microenvironment and its clinicopathological and prognostic associations in surgically resected cutaneous angiosarcoma.
Bi Y; Ge L; Ren X; Pang J; Zhao Y; Liang Z
Clin Transl Oncol; 2022 May; 24(5):941-949. PubMed ID: 35064455
[TBL] [Abstract][Full Text] [Related]
14. Refractory solitary cervical lymph node metastasis after esophageal squamous cell carcinoma surgery and its successful treatment with immune checkpoint inhibitor: A case report and literature review.
Song W; Wang H; Tian Y; Liu S; Chen X; Cui J; Zhao Y
Medicine (Baltimore); 2020 Mar; 99(10):e19440. PubMed ID: 32150096
[TBL] [Abstract][Full Text] [Related]
15. Antiprogrammed cell death protein 1 immunotherapy for angiosarcoma with high programmed death-ligand 1 expression: a case report.
Xu F; Zheng J; Fu M; Zhou H
Immunotherapy; 2020 Aug; 12(11):771-776. PubMed ID: 32611263
[No Abstract] [Full Text] [Related]
16. The concentration of programmed cell death-ligand 1 in the peripheral blood is a useful biomarker for esophageal squamous cell carcinoma.
Akutsu Y; Murakami K; Kano M; Toyozumi T; Matsumoto Y; Takahashi M; Otsuka R; Sekino N; Yokoyama M; Shiraishi T; Matsubara H
Esophagus; 2018 Apr; 15(2):103-108. PubMed ID: 29892935
[TBL] [Abstract][Full Text] [Related]
17. MAGE-A is More Highly Expressed Than NY-ESO-1 in a Systematic Immunohistochemical Analysis of 3668 Cases.
Kerkar SP; Wang ZF; Lasota J; Park T; Patel K; Groh E; Rosenberg SA; Miettinen MM
J Immunother; 2016 May; 39(4):181-7. PubMed ID: 27070449
[TBL] [Abstract][Full Text] [Related]
18. Programmed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinoma.
Kim R; Keam B; Kwon D; Ock CY; Kim M; Kim TM; Kim HJ; Jeon YK; Park IK; Kang CH; Kim DW; Kim YT; Heo DS
World J Gastroenterol; 2016 Oct; 22(37):8389-8397. PubMed ID: 27729745
[TBL] [Abstract][Full Text] [Related]
19. Clinical Benefit of First-Line Programmed Death-1 Antibody Plus Chemotherapy in Low Programmed Cell Death Ligand 1-Expressing Esophageal Squamous Cell Carcinoma: A Post Hoc Analysis of JUPITER-06 and Meta-Analysis.
Wu HX; Pan YQ; He Y; Wang ZX; Guan WL; Chen YX; Yao YC; Shao NY; Xu RH; Wang F
J Clin Oncol; 2023 Mar; 41(9):1735-1746. PubMed ID: 36473145
[TBL] [Abstract][Full Text] [Related]
20. Involvement of NY-ESO-1 and MAGE-A4 in the pathogenesis of desmoid tumors.
Hashimoto K; Nishimura S; Shinyashiki Y; Ito T; Kakinoki R; Akagi M
Medicine (Baltimore); 2023 Jun; 102(22):e33908. PubMed ID: 37266606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]